<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-125293</identifier>
<setSpec>1130-6343</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Comparative analysis of the safety of triple therapyvwith telaprevir between HCV monoinfected and HIV coinfected patients</dc:title>
<dc:description xml:lang="en">Purpose: To know the possible differences in the toxicity profile of triple therapy with telaprevir between monoinfected and coinfected patients. Method: A retrospective observational study (January 2012November 2013) of patients with HCV genotype 1, both monoinfected and coinfected with HIV, who had completed 12weeks of treatment with telaprevir. The necessary variables were collected to characterize patients and the treatment received. The classification was made according to the toxicity criteria of the Division of AIDS v.1.0. A descriptive and comparative statistical analysis using the SPSS v.15.0 software was performed. Results: 100 patients were included, 41% coinfected with HIV. Cirrhosis rate was observed at higher coinfected patients(97.6% vs 52.5%, p &lt;0.001).Toxicity: increased incidence in coinfected hyperbilirubinemia(51.2% vs 27.1% p = 0.012). Toxicity grades: no differences in mild-moderate toxicity were observed between the two groups, while severe hyperbilirubinemia was higher in coinfected (26.8%vs 3.4% p = 0.001). Increased use of exogenous erythropoietin(39.9% vs 12.2% p = 0.003) was observed, and dose adjustment of ribavirin (64.4% vs 26.8% p &lt;0.001) in monoinfected patients. Conclusions: The study shows a similar toxicity profile between the two groups except for hyperbilirubinemia appears greater in coinfected patients (possibly related to the use of at azanavir)and less use of exogenous erythropoietin and dose reduction of ribavirin in them (AU)</dc:description>
<dc:creator>Maiques Llácer, F. J</dc:creator>
<dc:creator>Soler Company, E</dc:creator>
<dc:creator>Sangrador Pelluz, C</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo: Conocer las posibles diferencias en cuanto al perfil de toxicidad de la triple terapia con telaprevir entre pacientes monoinfectados y coinfectados. Método: Estudio observacional retrospectivo (Enero 2012Noviembre 2013) de los pacientes con VHC genotipo 1, tanto monoinfectados como coinfectados por VIH, que hubieran finalizado las 12 semanas de tratamiento con telaprevir. Se recogieron las variables necesarias para caracterizar a los pacientes, y aquellas referentes al tratamiento recibido. La clasificación de la toxicidad se realizó según criterios de la División del SIDA v.1.0. Se realizó un análisis estadístico descriptivo y comparativo empleando el programa SPSS v.15.0.Resultados: Se incluyeron 100 pacientes, 41% coinfectado con el VIH. Se observó una tasa de cirrosis hepática superior en pacientes coinfectados (97,6% vs 52,5% p &lt; 0,001).Toxicidad: mayor incidencia hiperbilirrubinemia en coinfectados(51,2% vs 27,1% p = 0,012). Toxicidad por grados: no se observaron diferencias  en la toxicidad leve-moderada entre ambos grupos, mientras que la hiperbilirrubinemia grave fue mayor enlos pacientes coinfectados (26,8% vs 3,4% p = 0,001).Se observó mayor empleo de eritropoyetina exógena (39,9% vs12,2% p = 0,003), y de ajuste de dosis de ribavirina (64,4% vs26,8% p &lt; 0,001) en pacientes monoinfectados. Conclusiones: Se evidencia un perfil de toxicidad similar entre (.. )(AU)</dc:description>
<dc:source>Farm Hosp;38(1): 25-29, ene.-feb. 2014. tab</dc:source>
<dc:identifier>ibc-125293</dc:identifier>
<dc:title xml:lang="es">Análisis comparativo de la seguridad de la triple terapia bcon telaprevir entre pacientes monoinfectados por VHC  y coinfectados por VIH</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d24718^s22057</dc:subject>
<dc:subject>^d38332^s22079</dc:subject>
<dc:subject>^d11924^s22079</dc:subject>
<dc:subject>^d29416^s22052</dc:subject>
<dc:subject>^d33344^s22057</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d31852^s22052</dc:subject>
<dc:subject>^d54468^s22057</dc:subject>
<dc:subject>^d12663^s22073</dc:subject>
<dc:subject>^d22780</dc:subject>
<dc:type>article</dc:type>
<dc:date>201402</dc:date>
</metadata>
</record>
</ibecs-document>
